Bawei Chenxiang Wan ameliorates right ventricular hypertrophy in rats with high altitude heart disease by SIRT3-HIF1α-PDK/PDH signaling pathway improving fatty acid and glucose metabolism
Yiwei Han,
Shadi Li,
Zhiying Zhang
et al.
Abstract:Background
Bawei Chenxiang Wan (BCW) is among the most effective and widely used therapies for coronary heart disease and angina pectoris in Tibet. However, it is unknown whether it confer protection through right ventricle (RV) myocardial metabolic mechanism.
Methods
Male Sprague–Dawley rats were oral administration BCW, injected concurrently with a bolus of Sugen5416 (SU5416) and hypoxia exposure (5000m altitude) for 4 weeks(SuHx). Right ventricular hypertrophy (RVH) in high altitude heart disease (HAHD) was… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.